Tibial Fractures
📧 Sign up to get email alerts when something new happens for Tibial Fractures.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: Conjoint Analysis of Patient Preferences in Joint Interventions [NA]
This clinical trial update notes that the study on conjoint analysis of patient preferences in joint interventions sponsored by Duke Univers…
-
CLINICAL_TRIALS trial_result · 2023-09-21Clinical Trial Update: Management of Traumatic Bone Defects in Tibial Plateau Fractures With Antibiotic-Impregnated Biodegradable Calcium Sulfate Beads: A Prospective Clinical Trial [NA]
Prospective clinical trial evaluating antibiotic-impregnated biodegradable calcium sulfate beads for managing traumatic bone defects in tibi…
-
CLINICAL_TRIALS trial_result · 2021-11-02Clinical Trial Update: A Multicenter Randomized Trial Comparing IM Nails and Plate Fixation in Proximal Tibial Fractures [NA]
A multicenter randomized trial comparing intramedullary nails and plate fixation for proximal tibial fractures has completed with posted res…
-
CLINICAL_TRIALS withdrawal · 2020-01-23Clinical Trial Update: Bone Healing Accelerant Versus Standard of Care for Open Tibia Fractures [Phase 3]
Phase 3 trial investigating a bone healing accelerant for open tibia fractures has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2018-08-17Clinical Trial Update: Intra-articular Local Anesthetic Injection and Hematoma Aspiration [Phase 4]
Phase 4 trial update on intra-articular local anesthetic injection and hematoma aspiration for tibial fractures; study terminated with resul…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-03-13Clinical Trial Update: rhBMP-2 Versus Autograft in Critical Size Tibial Defects [Phase 4]
Phase 4 trial comparing rhBMP-2 to autograft for critical size tibial defects was terminated; results posted in 2018.
-
EMA withdrawal · 2016-07-27EMA Withdrawn: Osigraft (eptotermin alfa) — Olympus Biotech International Limited
The EMA withdrew Osigraft (eptotermin alfa) from the market for tibial fracture indications.